- Home
- SRTS vs CGTX Comparison
SRTS vs CGTX Comparison
Compare SRTS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- CGTX
- Stock Information
- Founded
- SRTS 2010
- CGTX 2007
- Country
- SRTS United States
- CGTX United States
- Employees
- SRTS N/A
- CGTX N/A
- Industry
- SRTS Medical/Dental Instruments
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- SRTS Health Care
- CGTX Health Care
- Exchange
- SRTS Nasdaq
- CGTX Nasdaq
- Market Cap
- SRTS 118.2M
- CGTX 16.1M
- IPO Year
- SRTS 2016
- CGTX 2021
- Fundamental
- Price
- SRTS $6.64
- CGTX $0.71
- Analyst Decision
- SRTS Strong Buy
- CGTX Strong Buy
- Analyst Count
- SRTS 2
- CGTX 6
- Target Price
- SRTS $12.50
- CGTX $8.30
- AVG Volume (30 Days)
- SRTS 244.3K
- CGTX 18.9M
- Earning Date
- SRTS 02-06-2025
- CGTX 11-13-2024
- Dividend Yield
- SRTS N/A
- CGTX N/A
- EPS Growth
- SRTS N/A
- CGTX N/A
- EPS
- SRTS 0.57
- CGTX N/A
- Revenue
- SRTS $41,308,000.00
- CGTX N/A
- Revenue This Year
- SRTS $65.04
- CGTX N/A
- Revenue Next Year
- SRTS $24.87
- CGTX N/A
- P/E Ratio
- SRTS $11.51
- CGTX N/A
- Revenue Growth
- SRTS 65.62
- CGTX N/A
- 52 Week Low
- SRTS $2.61
- CGTX $0.34
- 52 Week High
- SRTS $9.33
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- SRTS 37.42
- CGTX 55.44
- Support Level
- SRTS $6.38
- CGTX $0.67
- Resistance Level
- SRTS $7.62
- CGTX $0.90
- Average True Range (ATR)
- SRTS 0.44
- CGTX 0.09
- MACD
- SRTS -0.07
- CGTX -0.00
- Stochastic Oscillator
- SRTS 19.70
- CGTX 43.60
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.